What happened
What a difference a week can make to a volatile stock. Following a significant swoon late last week, BioXcel Therapeutics (NASDAQ: BTAI) sharply reversed course in the subsequent frame. As of early Friday morning, according to data compiled by S&P Global Market Intelligence, its share price had rocketed more than 63% higher week to date.
So what
The monster sell-off occurred last Thursday, after BioXcel released the results from a phase 3 clinical trial of its BXCL501, a therapy that targets the agitation suffered by Alzheimer's disease patients. The results were encouraging, with the drug meeting its primary efficacy endpoint. It was also well tolerated, and produced no serious adverse events.
That wasn't the source of the concern, though. It soon came to light that an investigator at one of the trial's sites might not have been entirely honest in communicating about a significant side effect of the medication. Any alarm bell that relates to a biotech's clinical process is going to rattle the market.
Investors clearly thought their initial, panicky reaction was overblown -- after all, BXCL501 tested well at the end of the day, and that's the factor that really matters. This explains the big leap the stock has enjoyed over the past few trading days.
Now what
It also seems like BXCL501 has a good future ahead of it. BioXcel said that it plans to submit a supplemental New Drug Application (NDA) later this year with the U.S. Food and Drug Administration (FDA). According to the company, there are currently around 100 million Alzheimer's disease-related agitation episodes per year in the U.S. alone, providing a potentially large and deep market for the medication.
10 stocks we like better than BioXcel Therapeutics
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and BioXcel Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of July 3, 2023
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
